Definium Therapeutics (NASDAQ:DFTX) Hits New 52-Week High – Still a Buy?

Definium Therapeutics, Inc. (NASDAQ:DFTX) shares reached a new 52-week high on Monday . The company traded as high as $26.14 and last traded at $26.14, with a volume of 217305 shares. The stock had previously closed at $22.68.

Analyst Upgrades and Downgrades

Several research analysts recently weighed in on the stock. Wolfe Research started coverage on shares of Definium Therapeutics in a research report on Monday, February 23rd. They issued an “outperform” rating and a $25.00 price objective for the company. Weiss Ratings reiterated a “sell (d-)” rating on shares of Definium Therapeutics in a research report on Thursday, January 22nd. Royal Bank Of Canada upped their price objective on Definium Therapeutics from $20.00 to $36.00 and gave the company an “outperform” rating in a report on Friday, January 23rd. Stifel Nicolaus set a $30.00 price target on shares of Definium Therapeutics and gave the stock a “buy” rating in a research report on Thursday. Finally, Needham & Company LLC reaffirmed a “buy” rating on shares of Definium Therapeutics in a research note on Monday, January 5th. Three research analysts have rated the stock with a Strong Buy rating, ten have issued a Buy rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the company currently has a consensus rating of “Buy” and a consensus price target of $37.42.

Definium Therapeutics Stock Performance

The company has a debt-to-equity ratio of 0.12, a current ratio of 6.29 and a quick ratio of 6.29. The company has a fifty day moving average price of $18.64 and a two-hundred day moving average price of $15.20. The company has a market capitalization of $2.32 billion, a P/E ratio of -10.90 and a beta of 2.44.

Institutional Investors Weigh In On Definium Therapeutics

Hedge funds have recently added to or reduced their stakes in the company. CenterBook Partners LP bought a new stake in Definium Therapeutics during the 3rd quarter worth approximately $1,880,000. Boxer Capital Management LLC bought a new position in Definium Therapeutics during the third quarter valued at about $1,928,000. Royce & Associates LP purchased a new stake in Definium Therapeutics during the third quarter worth about $955,000. Rosalind Advisors Inc. raised its position in Definium Therapeutics by 78.6% in the third quarter. Rosalind Advisors Inc. now owns 750,000 shares of the company’s stock worth $8,842,000 after acquiring an additional 330,000 shares during the period. Finally, GSA Capital Partners LLP purchased a new position in Definium Therapeutics in the third quarter valued at about $654,000. Institutional investors and hedge funds own 27.91% of the company’s stock.

About Definium Therapeutics

Definium Therapeutics, Inc, a clinical stage biopharmaceutical company, develops novel products to treat brain health disorders. The company’s lead product candidates include MM120, which is in phase 3 for the treatment of generalized anxiety disorder and attention deficit hyperactivity disorder; and DT402, a R-enantiomer of 3,4-methylenedioxymethamphetamine, which is in phase 2a clinical trials for the treatment of core symptoms of autism spectrum disorder. The company was formerly known as Mind Medicine (MindMed) Inc and changed its name to Definium Therapeutics, Inc in January 2026.